arrow
T

Takayuki Kinoshita

breast surgery
H指数:41
被引数:6,583

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)

射频消融作为早期乳腺癌保乳手术的潜在替代方案:多中心、单臂、III期RAFAELO研究(NCCH1409)的5年结果

2026-02-180
PRE
Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies

通过五项研究的综合分析验证95-gene classifier(95GC)对复发的预测能力及其临床应用价值

2025-06-250
PRE
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status

2021年国家临床数据库—乳腺癌登记系统年度报告:按体重指数和绝经状态分类的特征

2025-04-210
OA
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression
2025-02-060
OAAI
Prediction of tissue-of-origin of early stage cancers using serum miRNomes

使用血清miRNomes预测早期癌症的起源组织

2022-11-2517
OAAI
A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study
CANCER
IF5.1
2022-02-286
OAAI
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study
2020-08-207
PREAI
Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: The habit-B randomized controlled trial in progress
2020-02-151
PRE
Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial)
2020-02-151
PRE